PPARs as drug targets to modulate inflammatory responses?

Curr Drug Targets Inflamm Allergy. 2004 Dec;3(4):361-75. doi: 10.2174/1568010042634578.

Abstract

The three peroxisome proliferator-activated receptors (PPARs) isotypes (PPAR alpha, beta/delta and gamma) belong to the nuclear hormone receptor family. During the last decade, they have been identified as anti-inflammatory transcription factors. Part of this regulation antiinflammatory is mediated through negative interference between PPARs and other nuclear factors such as NFkB, AP-1 and C/EBP, which regulate innate as well as adaptative immunity. In addition, the PPARs control the functions of macrophages, B cells and T cells. In this review, we summarise the pathways through which the PPARs control inflammatory responses. We also discuss the potential utilisation of PPAR specific ligands in the treatment of inflammatory diseases, such as inflammatory bowel diseases, atherosclerosis, Parkinson's and Alzheimer's diseases.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / pharmacology
  • Anti-Inflammatory Agents / therapeutic use*
  • Humans
  • Immunity, Active
  • Immunity, Innate
  • Inflammation / drug therapy*
  • Inflammation / immunology
  • Peroxisome Proliferator-Activated Receptors / drug effects*
  • Peroxisome Proliferator-Activated Receptors / physiology

Substances

  • Anti-Inflammatory Agents
  • Peroxisome Proliferator-Activated Receptors